Hep Summer 2016 - Special Issue
Hep Summer 2016 - Special Issue
In every issue of HEP, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
Feature
Super Friend: Gloria Guzman Inspires Others Hoping for a Hep C Cure
As a peer educator, Gloria Guzman inspires others hoping for a hepatitis C cure.
From the Editor
What a Wonderful World
Regardless of the hurdles many HCV-positive people face, there is a better chance to get cured than ever before.
News
Youthful Drug Use Not to Blame?
Another explanation for hep C among baby boomers
Screening Among Baby Boomers Is Inadequate
People on Medicaid are less likely to be treated.
Cherokee Nation Seeks Complete Elimination of Hep C
They are the first community in the United States to set this goal
Hep C Health Insurance Discrimination
An analysis from Harvard University
U.S. Addiction Treatment Is Hard to Get
More difficult than getting drugs that cause addiction
Treatment News
Hepatitis B and C Drive Liver Cancer Rates
Liver cancer incidence is steadily rising in the United States, driven by hepatitis B and C virus infection in an aging population.
Expanded Approval for Daklinza/Sovaldi
The FDA expanded the approved uses of the combination hep C virus regimen of Bristol-Myers Squibb’s Daklinza and Gilead Sciences’ Sovaldi.
Treating Hepatitis C Earlier Is More Cost Effective
Using Gilead Sciences’ Harvoni to treat hep C in certain people is more cost effective than waiting until their liver disease progresses.
Hep C and Heart Disease Link
People with hep C virus (HCV) have higher rates of cardiovascular disease (CVD) than HCV-negative individuals with similar risk factors.
FDA OKs Merck’s Zepatier
The FDA has approved Merck’s once-daily, fixed-dose combination tablet Zepatier to treat people with genotypes 1 and 4 of hep C.
